SCHEDULE: T. Rowe Price Discloses 8.3% Stake in QuidelOrtho

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 8.3% of QuidelOrtho Corp.'s common stock as of March 31, 2026.

Summary

• T. Rowe Price Investment Management, Inc. has reported a significant ownership stake in QuidelOrtho Corp.
• As of March 31, 2026, the firm beneficially owns 5,629,965 shares of QuidelOrtho's common stock.
• This ownership represents approximately 8.3% of the total class of securities.
• The filing is an amendment (Amendment No. 5) to a Schedule 13G, indicating a change or update in their holdings.
• T. Rowe Price Investment Management, Inc. is identified as an investment adviser.
• The company explicitly denies beneficial ownership for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports an investment position and does not contain operational or financial updates for QuidelOrtho itself, nor does it indicate any intent to influence control.

Positives

• T. Rowe Price Investment Management, Inc. has taken a substantial position in QuidelOrtho, which could signal confidence in the company's future prospects.
• The filing indicates a clear and substantial ownership percentage (8.3%), providing transparency to the market regarding a major institutional investor's stake.

Negatives

• The filing does not contain any negative financial results or operational challenges for QuidelOrtho itself; it solely reports an investment position.
• The explicit denial of beneficial ownership for control purposes might suggest the stake is purely for investment and not an attempt to influence management, which could be seen as neutral or slightly negative by some activist investors.

Risks

• The primary risk associated with this filing is the potential for significant share trading activity by T. Rowe Price Investment Management, Inc., which could impact QuidelOrtho's stock price.
• While not explicitly stated as a risk in the filing, a large institutional investor's stake could attract regulatory scrutiny or lead to increased market volatility if their position changes significantly.

Future Outlook

The filing does not contain forward-looking statements or guidance from QuidelOrtho Corp. It solely reports the investment position of T. Rowe Price Investment Management, Inc.

Management Comments

• T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that significant stake filings by major investment management firms like T. Rowe Price are common in the healthcare sector, often indicating a belief in the company's long-term value or strategic positioning. This filing places QuidelOrtho within the focus of large institutional capital.

Stakeholder Impact

• Shareholders: The significant stake may influence market perception and potentially stock price due to the presence of a large institutional investor.
• Management: While T. Rowe Price explicitly denies seeking control, a substantial stake can still lead to increased engagement or dialogue with management.
• Analysts: The filing provides data for analysts to incorporate into their valuation models and investor sentiment assessments.

Next Steps

• Monitor future filings from T. Rowe Price Investment Management, Inc. for any changes in their stake in QuidelOrtho Corp.
• Observe QuidelOrtho Corp.'s performance and strategic announcements for potential reasons behind the investment.

Key Dates

Keywords

QuidelOrtho Corp, T. Rowe Price Investment Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management